Security
Minerva Neurosciences, Inc Common Stock · NERV
NERVNASDAQCommon stockCurrentCIK 1598646Updated Oct 28, 2026
NERV price & chart
Loading TradingView…
NASDAQ:NERV on TradingView ↗About the company
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is conducting a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.
In the news
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
4 filing
Show 5 more recent filings
4 filing
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 3.03, 5.03, 5.07, 9.01
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
424B5 filing
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 28,092,052Source | 42,812,338Source | 95,088,945Source | 30,419,645Source | 46,290,837Source | 94,027,156Source | 32,798,326Source | 50,510,415Source | 97,968,888Source | 37,143,744Source | 56,899,750Source | 55,087,233Source |
| Property, Plant and Equipment, NetUSD | 1,360Source | 6,802Source | — | 2,721Source | 8,163Source | — | 4,081Source | 9,524Source | 0Source | 5,442Source | 10,884Source | 16,326Source |
| GoodwillUSD | 14,869,399Source | 14,869,399Source | 14,869,399Source | 14,869,399Source | 14,869,399Source | 14,869,399Source | 14,869,399Source | 14,869,399Source | 14,869,399Source | 14,869,399Source | 14,869,399Source | 14,869,399Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 12,286,646Source | 26,528,792Source | 24,652,086Source | 15,247,910Source | 30,881,000Source | 32,659,770Source | 17,290,048Source | 34,818,304Source | 82,301,813Source | 21,362,008Source | 40,912,575Source | 36,093,606Source |
| Assets, CurrentUSD | 13,020,179Source | 27,936,137Source | 79,732,517Source | 15,547,525Source | 31,409,018Source | 79,106,779Source | 17,924,846Source | 35,620,850Source | 83,099,489Source | 22,268,903Source | 42,002,440Source | 40,158,941Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 62,672,322Source | 64,483,040Source | 296,648,246Source | 62,528,858Source | 90,782,452Source | 343,079,094Source | 61,947,169Source | 87,097,861Source | 233,755,048Source | 62,836,844Source | 85,357,240Source | 75,111,452Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 699Source | 699Source | 4,723Source | 699Source | 699Source | 4,384Source | 699Source | 699Source | 4,327Source | 699Source | 699Source | 534Source |
| Retained Earnings (Accumulated Deficit)USD | -405,132,077Source | -391,104,515Source | -796,737,839Source | -402,388,123Source | -413,617,720Source | -814,204,124Source | -399,129,535Source | -405,384,233Source | -688,799,740Source | -395,376,563Source | -396,815,428Source | -366,810,075Source |
| Stockholders' Equity Attributable to ParentUSD | -34,580,270Source | -21,670,702Source | -213,300,623Source | -32,109,213Source | -44,491,615Source | -254,013,860Source | -29,148,843Source | -36,587,446Source | -140,748,082Source | -25,693,100Source | -28,457,490Source | -20,024,219Source |
| Additional Paid in Capital, Common StockUSD | 370,551,108Source | 369,433,114Source | 583,432,493Source | 370,278,211Source | 369,125,406Source | 560,185,880Source | 369,979,993Source | 368,796,088Source | 548,047,331Source | 369,682,764Source | 368,357,239Source | 346,785,322Source |
| Liabilities and EquityUSD | 28,092,052Source | 42,812,338Source | 95,088,945Source | 30,419,645Source | 46,290,837Source | 94,027,156Source | 32,798,326Source | 50,510,415Source | 97,968,888Source | 37,143,744Source | 56,899,750Source | 55,087,233Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,672,322Source | 4,483,040Source | 3,958,061Source | 2,528,858Source | 4,203,406Source | 4,482,193Source | 1,947,169Source | 2,830,795Source | 2,290,473Source | 2,836,844Source | 3,340,417Source | 1,377,576Source |
| Accounts Payable, CurrentUSD | 944,492Source | 553,192Source | 1,447,556Source | 896,799Source | 828,345Source | 2,118,225Source | 639,946Source | 1,435,568Source | 639,707Source | 1,607,844Source | 1,805,320Source | 969,667Source |
| Additional Financial Items | ||||||||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 431Source | 891Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -125,404,384Source | -3,752,972Source | -293,423,177Source | 1,438,865Source | -30,005,353Source | -32,108,676Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | —Source | —Source | —Source | —Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 8,710,302Source | 297,229Source | 1,327,372Source | 1,325,525Source | 1,968,381Source | 4,108,819Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,465,073Source | -967,898Source | -1,059,012Source | -197,476Source | 835,653Source | -883,548Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -5,427,064Source | -4,071,960Source | -13,510,936Source | -19,550,567Source | -14,784,732Source | -24,645,143Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -45,294,104Source | 0Source | 0Source | 0Source | — | -16,326Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 16,326Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 1,079,125Source | 0Source | 74,450,741Source | — | 19,603,701Source | -5Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -49,642,043Source | -4,071,960Source | 60,939,805Source | -19,550,567Source | 4,818,969Source | -24,661,474Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 12,386,646Source | 26,628,792Source | 24,752,086Source | 15,347,910Source | 32,759,770Source | 17,390,048Source | 82,401,813Source | 21,462,008Source | 41,012,575Source | 36,193,606Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 272,897Source | 307,708Source | 2,272,840Source | 298,218Source | 8,710,302Source | 297,229Source | 1,327,372Source | 1,325,525Source | 1,968,381Source | 4,108,819Source |
| Capitalized Computer Software, AmortizationUSD | — | — | — | — | — | — | — | 0Source | — | 17,027Source | 25,540Source | 8,513Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -6,246Source | -13,108Source | -14,351Source | -21,110Source | -1,804Source | -8,376Source | -56,555Source | -1,926Source | -40,235Source | -27,741Source |
| General and Administrative ExpenseUSD | — | — | 1,918,971Source | 2,478,787Source | 3,454,924Source | 2,076,108Source | 11,416,586Source | 2,540,446Source | 9,343,497Source | 9,949,791Source | 10,414,323Source | 10,582,239Source |
| GoodwillUSD | — | — | 14,869,399Source | 14,869,399Source | 14,869,399Source | 14,869,399Source | 14,869,399Source | 14,869,399Source | 14,869,399Source | 14,869,399Source | 14,869,399Source | 14,869,399Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | 106,640Source | 313,967Source | 569,591Source | 136,671Source | 629,602Source | 158,288Source | 948,122Source | 1,272,354Source | 1,437,405Source | 556,946Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,743,954Source | 22,513,205Source | 17,466,285Source | -3,258,588Source | -125,404,384Source | -3,752,972Source | -293,423,177Source | 1,438,865Source | -30,005,353Source | -32,108,676Source |
| Operating ExpensesUSD | — | — | 2,844,348Source | 4,366,700Source | 10,642,159Source | 3,374,149Source | 16,671,552Source | 3,902,884Source | 15,102,970Source | 21,848,386Source | 23,119,576Source | 25,231,326Source |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Operating Income (Loss)USD | — | — | -2,844,348Source | -4,366,700Source | -10,642,159Source | -3,374,149Source | -16,671,552Source | -3,902,884Source | -15,102,970Source | -21,848,386Source | -23,119,576Source | -25,231,326Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | -32,108,676Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,743,954Source | 22,513,205Source | 17,466,285Source | -3,258,588Source | -125,404,384Source | -3,752,972Source | -293,423,177Source | 1,438,865Source | -30,005,353Source | -32,108,676Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.36Source | 2.97Source | 0.36Source | -0.43Source | -2.86Source | -0.5Source | -34.67Source | 0.19Source | -4.61Source | -6.01Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.36Source | 2.97Source | -0.14Source | -0.43Source | -2.86Source | -0.5Source | -34.67Source | 0.19Source | -4.61Source | -6.01Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 7,568,981Source | 7,568,981Source | 46,599,044Source | 7,568,981Source | 43,900,426Source | 7,568,981Source | 8,463,581Source | 7,568,981Source | 6,506,372Source | 5,340,194Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 7,568,981Source | 7,568,981Source | 79,104,585Source | 7,568,981Source | 43,900,426Source | 7,568,981Source | 8,463,581Source | 7,573,763Source | 6,506,372Source | 5,340,194Source |
| Additional Financial Items | ||||||||||||
| Capitalized Computer Software, AmortizationUSD | — | — | — | — | — | — | — | 0Source | — | 17,027Source | 25,540Source | 8,513Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | 1,361Source | 5,442Source | 5,442Source | 5,442Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -6,246Source | -13,108Source | -14,351Source | -21,110Source | -1,804Source | -8,376Source | -56,555Source | -1,926Source | -40,235Source | -27,741Source |
| General and Administrative ExpenseUSD | — | — | 1,918,971Source | 2,478,787Source | 3,454,924Source | 2,076,108Source | 11,416,586Source | 2,540,446Source | 9,343,497Source | 9,949,791Source | 10,414,323Source | 10,582,239Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | 106,640Source | 313,967Source | 569,591Source | 136,671Source | 629,602Source | 158,288Source | 948,122Source | 1,272,354Source | 1,437,405Source | 556,946Source |
| Operating ExpensesUSD | — | — | 2,844,348Source | 4,366,700Source | 10,642,159Source | 3,374,149Source | 16,671,552Source | 3,902,884Source | 15,102,970Source | 21,848,386Source | 23,119,576Source | 25,231,326Source |
| Other IncomeUSD | — | — | — | 26,579,046Source | — | — | — | — | — | 26,579,046Source | — | — |
| Research and Development ExpenseUSD | — | — | 925,377Source | 1,887,913Source | 7,187,235Source | 1,298,041Source | 5,254,966Source | 1,362,438Source | 5,759,473Source | 11,898,595Source | 12,705,253Source | 14,649,087Source |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Undistributed Earnings (Loss) Allocated to Participating Securities, Basic | — | — | — | — | —Source | — | — | — | — | — | — | — |
Offerings
Registration 333-294203
Filing attachments
d22348dex991.htm · 8-K · 2026-08-07
EX-99.1 2 d22348dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Scientific Advisory Board of leading experts in psychiatry and neuroscience established to guide the confirmatory Phase 3 trial of roluperidone Roluperidone remains the only late-stage drug candidate for this high-need population BURLIN…
Read attachment ↗d947378dex991.htm · 8-K · 2026-05-05
EX-99.1 2 d947378dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug - drug interaction concerns with roluperidone and olanzapine Roluperidone remains the only late-stage drug candidate for this high-need population…
Read attachment ↗d143634dex991.htm · 8-K · 2026-04-02
EX-99.1 4 d143634dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Minerva Announces Leadership Transition Jim O’Connor joins as Chief Business Officer and General Counsel BURLINGTON, Mass., April 2, 2026 (GLOBE NEWSWIRE) - Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced a leadership transition with the appointment of Jim O’Connor as Chief Business Officer (CBO)…
Read attachment ↗d71904dex410.htm · S-3 · 2026-03-11
Exhibit 4.10 MINERVA NEUROSCIENCES, INC. AND _____________, A S W ARRANT A GENT F ORM OF D EBT S ECURITIES W ARRANT A GREEMENT D ATED A S O F __________ M INERVA N EUROSCIENCES, I NC. F ORM OF D EBT S ECURITIES W ARRANT A GREEMENT T HIS D EBT S ECURITIES W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between M INERVA N EUROSCIENCES, I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•…
Read attachment ↗d71904dex46.htm · S-3 · 2026-03-11
Exhibit 4.6 MINERVA NEUROSCIENCES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities T ABLE O F C ONTENTS PAGE ARTICLE 1 DEFINITIONS 4 Section 1.01 …
Read attachment ↗d71904dex48.htm · S-3 · 2026-03-11
Exhibit 4.8 M INERVA N EUROSCIENCES, I NC. AND _____________, A S W ARRANT A GENT F ORM OF C OMMON S TOCK W ARRANT A GREEMENT D ATED A S O F __________ M INERVA N EUROSCIENCES, I NC. F ORM OF C OMMON S TOCK W ARRANT A GREEMENT T HIS C OMMON S TOCK W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between M INERVA N EUROSCIENCES, I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and h…
Read attachment ↗